Since 2011 the Food and Drugs Administration (FDA) approved an antibody against CTLA-4 (ipilimumab), two antibodies against PD-1 (pembrolizumab and nivolumab), and against PD-1 ligand 1 (atezolizumab and durvalumab) for cancer treatment. This evidence concerns the gene PDCD1 and cancer.